Evidence map›Paper›PMID 36645076›Full record

ArticleDisease models & mechanisms2023

Patient-specific variants of NFU1/NFU-1 disrupt cholinergic signaling in a model of multiple mitochondrial dysfunctions syndrome 1.

Peter A Kropp, Philippa Rogers, Sydney E Kelly, Rebecca McWhirter, Willow D Goff, Ian M Levitan, David M Miller, Andy Golden

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peter A KroppLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-2977-6123
Philippa RogersLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sydney E KellyLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Rebecca McWhirterDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37235, USA.
Willow D GoffLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ian M LevitanLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
David M MillerDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37235, USA.
Andy GoldenLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USVanderbilt University · US

Funding

Discovery and analysis of the C. elegans neuronal gene expression network (CENGEN)R01NS100547 · NINDS · YALE UNIVERSITY · PI MARC HAMMARLUND, Oliver Hobert · 2017 to 2026
$11.2M
The Investigation of disease causing genes in C. elegansZIADK075075 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GOLDEN, ANDY · 2012 to 2023
$9.0M
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Aric L Daul, Ann E. Rougvie · 2012 to 2026
$7.5M
Molecular Genetics of Synaptic PlasticityR01NS106951 · NINDS · VANDERBILT UNIVERSITY · PI BIANCHI, LAURA, MILLER, DAVID M · 2018 to 2022
$2.2M
Molecular mechanisms for neuron-specific assembly of electrical synapsesR01NS113559 · NINDS · VANDERBILT UNIVERSITY · PI MILLER, DAVID M · 2020 to 2024
$1.8M
NIH HHS P40 OD010440NINDS NIH HHS R01 NS100547NINDS NIH HHS R01 NS106951NINDS NIH HHS R01 NS113559
6 · The paper itself

Abstract

Neuromuscular dysfunction is a common feature of mitochondrial diseases and frequently presents as ataxia, spasticity and/or dystonia, all of which can severely impact individuals with mitochondrial diseases. Dystonia is one of the most common symptoms of multiple mitochondrial dysfunctions syndrome 1 (MMDS1), a disease associated with mutations in the causative gene (NFU1) that impair iron-sulfur cluster biogenesis. We have generated Caenorhabditis elegans strains that recreated patient-specific point variants in the C. elegans ortholog (nfu-1) that result in allele-specific dysfunction. Each of these mutants, Gly147Arg and Gly166Cys, have altered acetylcholine signaling at neuromuscular junctions, but opposite effects on activity and motility. We found that the Gly147Arg variant was hypersensitive to acetylcholine and that knockdown of acetylcholine release rescued nearly all neuromuscular phenotypes of this variant. In contrast, we found that the Gly166Cys variant caused predominantly postsynaptic acetylcholine hypersensitivity due to an unclear mechanism. These results are important for understanding the neuromuscular conditions of MMDS1 patients and potential avenues for therapeutic intervention.

Indexed as

DystoniaMitochondrial DiseasesAcetylcholineAnimalsCaenorhabditis elegansCarrier ProteinsCholinergic AgentsAcetylcholineCarrier ProteinsCholinergic AgentsNFU1 protein, humanAcetylcholineC. elegansGABAMitochondriaMMDS1Motility

Identifiers

PMID36645076
PMCPMC9922734
OpenAlexW4316664308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.